Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
NCT05889585

Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant

Led by Gustave Roussy, Cancer Campus, Grand Paris · Updated on 2024-10-18

180

Participants Needed

1

Research Sites

100 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Intensified chemotherapy is an effective treatment in 30-70% of patients with refractory germ cell tumor. Since most cases are diagnosed before the age of 40, survivors can expect to live another 30 to 50 years after being successfully treated. Long-term side effects and physical and emotional consequences can therefore have a significant impact on daily life. To date, no data of this type is available in France. This study will help clinicians better understand the long-term consequences for relapsed patients receiving high-dose chemotherapy.

CONDITIONS

Official Title

Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age �3e�3d 18 years at diagnosis
  • Treated between 1990 and 2015
  • Histologically confirmed diagnosis of germ cell tumor (or high level serum tumor marker-based)
  • Treated for relapse with high-dose chemotherapy with autologous transplant at Gustave Roussy and relapse-free
  • Or treated by orchiectomy only with no evidence of relapse after at least 3 years
  • Or good or intermediate prognosis metastatic disease treated by first line cisplatin-based chemotherapy at Gustave Roussy, with no evidence of relapse
  • Ability to comply with the protocol procedures
  • Affiliated to a social security system or beneficiary of the same
  • Signed written informed consent prior to any study procedure
Not Eligible

You will not qualify if you...

  • Diagnosis of second malignancy
  • Any serious or unstable illness, or medical, social, or psychological condition that could affect safety, compliance, or study participation
  • Under guardianship or deprived of liberty by judicial or administrative decision
  • Incapable of giving informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Gustave Roussy

Villejuif, France, 94805

Actively Recruiting

Loading map...

Research Team

N

Natacha NAOUN, MD

CONTACT

K

Karim Fizazi, MD, Prof.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here